Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company focused on advancing cancer screening and precision oncology. Its primary purpose is to develop noninvasive tests that enable earlier detection and inform treatment decisions, most notably the Cologuard stool DNA test for colorectal cancer screening and the Oncotype DX suite that provides genomic insights to guide therapy selection. The company’s portfolio spans prevention, early detection, and treatment guidance, supported by collaborations with healthcare providers and institutions to broaden access and clinical adoption. Exact Sciences serves clinicians and patients across multiple cancer types and geographies, operating research and laboratory facilities that underpin assay development and validation. With ongoing innovation highlighted by large clinical programs and newer offerings in comprehensive tumor profiling, Exact Sciences plays a significant role in the healthcare ecosystem by supporting guideline-driven screening, reducing barriers to early diagnosis, and helping personalize oncology care pathways. Founded in 1995 and headquartered in Madison, Wisconsin, the company contributes to the diagnostics segment of the healthcare sector through scalable testing platforms and data-driven clinical evidence.